

Thursday, 7 July 2005

FOR IMMEDIATE RELEASE


OBJ announces first inductive coin-sized drug patch

OBJ Limited (OBJ) is pleased to announce that it has reached an advanced stage in the development of its coin-sized "smart" drug patch.

The "smart" patch is believed to be a world first intelligent solid-state drug patch and embodies the company's propriety *Dermaporation* through-the-skin drug delivery technology. Independent university trials have shown that this technology can increase drug delivery rates by up to 600% and can control both the dose rate and times of delivery across a number of commercially important drugs.

Unlike other drug patch technologies, the "smart patch" can deliver a range of drugs, hormones and cosmetically active compounds without the need to create new formulations.

This allows it to be used with existing drugs and compounds already in the market while avoiding the need for costly and time consuming re-approvals.



The re-usable coin-sized drug patch contains a complete microcomputer system and rechargeable power source and is expected to cost just a few dollars, making it competitive with current drug delivery solutions. A disposable single-use "smart" patch is also under development as well as a range of advanced programmable delivery patches for the cosmetic, physical therapy and general pharmacological markets.

-Ends-

OBJ Limited (ACN 056 482 636)

Ground Floor, 284 Oxford Street, Leederville, Western Australia 6007

Phone: +61 9 9443 3011 Fax: +61 9 9443 3866 Email: jedwards@obi.com.au

Background to the Announcement

OBJ Limited is a drug delivery company, developing electronic “drug patch” technologies that allow drugs, therapeutic agents and cosmetic compounds to be delivered more effectively and more efficiently through-the-skin.

The company had previously announced a 600% increase in the rate of delivery of the drug caffeine and a 70% reduction in the delivery times for the anaesthetic drugs lignocaine and prilocaine hydrochloride. More recently, it had demonstrated precise control over drug delivery rates and recent finding added an additional time-based control mechanism previously not seen in the drug delivery sector.

OBJ maintains a continues development and discovery program that currently includes a number of commercially significant anti-inflammatory, anti-pain, anti-oxidant and anti-cancer drugs, as well as a number of cosmetic compounds.

Sustainable Benefits

Through-the-skin delivery of drugs, hormones, vitamins, vaccines, anti-bodies and anti-aging molecules provides economic, safety and efficacy benefits to the pharmacology, medical, veterinary and cosmetic industries.

Cost reductions are achieved through self administration with a corresponding increase in safety and patient compliance.

Side effects can be reduced in many cases by localized delivery and programmed delivery rates. Needle stick injuries and needle disposable problems can be eliminated while the reduction in the level of skill required for application can significantly reduce total cost of administration.

Independence of Results

OBJ contracts its drug and technology testing programs to independent and respected organisations, such as Western Australian Biomedical Research Institute, Western Australian Institute for Medical Research, Curtin University of Technology and Murdoch University,

The high level of independence and international accreditation means that the results by OBJ can be published and presented at major medical and scientific conferences and forums.

For more information:

Jeffrey Edwards
Phone: +61 8 9443 3011
Mobile: 041 791 2211
E-mail: jedwards@obj.com.au